How the concept of biochemical response influenced the management of primary biliary cholangitis over time.

BACKGROUND Criteria assessing biochemical response to ursodeoxycholic acid (UDCA) are established risk stratification tools in primary biliary cholangitis (PBC). We aimed to evaluate to what extent liver tests influenced patient management during a three decade period, and whether this changed over time. METHODS 851 Dutch PBC patients diagnosed between 1988 and 2012 were reviewed to assess patient management in relation to liver test results during UDCA treatment. To do so, biochemical response at one year was analysed retrospectively according to Paris-1 criteria. RESULTS Response was assessable for 687/851 (81%) patients; 157/687 non-responders. During a follow-up of 8.8 years (IQR 4.8-13.9), 141 died and 30 underwent liver transplantation. Transplant-free survival of non-responders (60%) was significantly worse compared with responders (87%) (p < 0.0001). Management was modified in 46/157 (29%) non-responders. The most frequent change observed, noted in 26/46 patients, was an increase in UDCA dosage. Subsequently, 9/26 (35%) non-responders became responders within the next two years. Steroid treatment was started in one patient; 19 patients were referred to a tertiary centre. No trend towards more frequent changes in management over time was observed (p = 0.10). CONCLUSION Changes in medical management occurred in a minority of non-responders. This can largely be explained by the lack of accepted response criteria and of established second-line treatments for PBC. Nevertheless, the observation that response-guided management did not increase over time suggests that awareness of the concept of biochemical response requires further attention,particularly since new treatment options for PBC will soon become available.

[1]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[2]  Andrew K Burroughs,et al.  Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study , 2015, Gut.

[3]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[4]  C. Ponsioen,et al.  Rising incidence and prevalence of primary biliary cirrhosis: a large population‐based study , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[5]  J. Neuberger,et al.  Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. , 2014, Journal of hepatology.

[6]  D. Jones,et al.  P399 PBC MANAGEMENT AMONG CLINICIANS: GAPS IN CLINICAL COMPETENCE AND PRACTICE PERFORMANCE – SURVEY FINDINGS , 2014 .

[7]  S. Lens,et al.  Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[8]  T. Miyazaki,et al.  AUTOIMMUNE , CHOLESTATIC , AND BILIARY DISEASE Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid , 2013 .

[9]  G. Alexander,et al.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.

[10]  K. Lindor,et al.  Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[11]  O. Chazouilleres,et al.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.

[12]  K. Lindor,et al.  Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid , 2011, Alimentary pharmacology & therapeutics.

[13]  T. Arenovich,et al.  Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis , 2010, The American Journal of Gastroenterology.

[14]  G. Gores,et al.  American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis , 2010, Hepatology.

[15]  Y. Chrétien,et al.  Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. , 2010, Gastroenterologie clinique et biologique.

[16]  K. V. van Erpecum,et al.  Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.

[17]  M. Kaplan,et al.  Primary biliary cirrhosis , 1998, Hepatology.

[18]  F. Lammert,et al.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.

[19]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[20]  B. Hansen,et al.  Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients , 2006, The American Journal of Gastroenterology.

[21]  J. Rodés,et al.  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.

[22]  M. Färkkilä,et al.  Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial , 2005, Hepatology.

[23]  M. Abe,et al.  Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis , 2005, Journal of Gastroenterology.

[24]  T. Masaki,et al.  Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study , 2000, American Journal of Gastroenterology.

[25]  H. Ackermann,et al.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. , 1999, Gastroenterology.

[26]  T. Therneau,et al.  Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. , 1999, Journal of hepatology.

[27]  T. Therneau,et al.  Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. , 1999, Liver.

[28]  G. V. B. Henegouwen,et al.  A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg , 1998, Alimentary pharmacology & therapeutics.